CSL Invests $1.5 Billion to Expand Plasma Therapy Manufacturing Facility in Illinois

Specifications:

Name:

CSL Invests $1.5 Billion to Expand Plasma Therapy Manufacturing Facility in Illinois

Location:

Illinois, USA

Company:

CSL

Estimated Cost:

$1.5 Billio

Source:

https://newsroom.csl.com/

Introduction

CSL has announced a $1.5 billion expansion of its manufacturing facility in Kankakee, Illinois, to boost production of plasma-derived therapies and albumin. The project is aimed at improving access to treatments for patients with rare and serious diseases while supporting economic development in the local community.

Features

The expanded facility will feature CSL’s Horizon 2 manufacturing process, a patented technology designed to improve production efficiency and significantly increase immunoglobulin output from the same volume of plasma.

The expansion represents a major step in advancing manufacturing efficiency through the integration of innovative technologies and processes used in the production of plasma-based medicines.

As part of its strategy to expand medicines production capacity in the U.S., CSL expects the project to generate at least 300 new pharmaceutical jobs and around 800 construction and related roles in the local community. The Kankakee site currently employs more than 1,200 full-time staff. Since 2018, CSL has invested over $3 billion in its U.S. operations, creating more than 6,500 jobs and increasing its U.S. workforce to nearly 19,000 employees, accounting for around 60% of the company’s global workforce.

The Kankakee expansion is expected to become operational by 2031.